Explore Takeda's 2024 Annual Integrated Report showcasing our dedication to global health and a brighter future. Discover our corporate philosophy, sustainable value creation, and innovative biopharmaceutical approaches.
Semi-annual Report FY2023 – April 1, 2023 – March 31, 2024 147th Fiscal Year Annual Report 3rd Quarter Report 2nd Quarter Report 1st Quarter Report FY2022 – April 1, 2022 – March 31, 2023 146th Fiscal Year Annual Report 3rd Quarter Report 2nd Quarter Report 1st Quarter Report FY2021...
Additionally, Takeda’s corporate governance strategy as well as overall sustainability and Environmental, Social and Governance information are explained in detail in its 2023 Annual Integrated Report for the fiscal year ended March 31, 2022, which was issued on July 6. This report c...
“As highlighted at our R&D Day in December 2024, we are on track to three Phase 3 data readouts within calendar year 2025, strengthening confidence in our long-term growth outlook. “The announcement of our new share buyback program, approved by Takeda’s Board of Directors, demonstrates ou...
人免疫球蛋白 (Takeda): 一种Immunoglobulin调节剂药物,由Baxter International, Inc. (Baxter International, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: Immunoglobulin调节剂(免疫球蛋白调节剂),治疗领域: 肿瘤,免疫系统疾病,感染,在研适应症
the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Repor...
Takeda intends to use the proceeds from this transaction to reduce its debt and accelerate de-leveraging toward its target of 2x net debt/adjusted EBITDA within Fiscal Year 2021 –2023. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simpli...
the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s ...
the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F ...
the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s ...